Science
Adcentrx begins patient dosing in phase 1a/b study of ADRX─0405, a potential first─in─class ADC targeting STEAP1 to treat advanced solid tumours
Adcentrx Therapeutics (Adcentrx), a clinical─stage biotechnology company advancing innovative protein conjugates for cancer and other life─threatening diseases, announced the first patient dosed in the phase
By: pharmabiz
- Jan 09 2025
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS
Share this page
Guest Posts by Easy Branches
